Contact us
Young GI
Patients
Industry
Press
My Connect
Create myUEG account
About
To landing page
Who we are
Boards, Committees & Groups
Governance
Headquarters Management
History
What we do
Strategic Drivers
Year in Review
Our Members
Specialist Member Societies
National Member Societies
myUEG Community
myUEG Associates
My Connect
Women in GI
Young GIs
Researchers
Event Calendar
Week
To landing page
Attendance
Registration fees
Hotel
Venue
Helpful info
Travel info
Programme
Abstract Submission
Postgraduate Teaching
Nurse Programme
Hands-on
Information for Presenters
In-person Networking
myUEG Community Area
Learn from Leaders
Mentoring
The UEG Night
Let's Meet
Women in GI Networking
Industry Programme
Industry Exhibition
Industry Symposia
Meet the experts sessions
Innovation Hub
List of Supporters & Exhibitors
CME Accreditation
UEG Week on-demand
Future UEG Weeks
Education
To landing page
Online Education
Online Courses
Webinars
Career Development
Face-to-face Education
Summer School
Masterclass
Clinical Visiting Fellowships
Education Resources
Mistakes in...
UEG Talks Podcast
Image Hub
CME in Europe
Event Endorsement
Supporters
Research
To landing page
Support
Horizon Europe Support
Start-up Grant
Research Prize
Research Fellowship
Research Webinars
Research Projects
HoloSurge
Position Papers
White Book 2
Main Results
Full Reports
Materials and Presentations
Quality of Care
To landing page
Search Guidelines
Standards & Guidelines Repository
Non-English Guidelines
GI Guidelines App
Develop & Implement
How to develop guidelines
Guideline Endorsement
Guideline Webinars
Projects
Quality of Care Initiatives
Quality Standards
Public Affairs
To landing page
Advocacy
Core Positions
Stakeholder Collaboration
White Book 2
Position Papers
MEP Digestive Health Group
Our Supporters
#EUNewsline →
EU Elections 2024
Publications
To landing page
Publications
Congress Publications
Research Publications
Public Affairs Publications
Education Publications
UEG Publications
UEG Journal →
UEG Journal Podcast
White Book 2
Opportunities
To landing page
Congress Opportunities
Top Abstract Prizes
National Scholar Award
Travel Grants
International Scholarship Awards
Research Funding
Research Prize
Research Fellowship
Horizon Europe Support
Start-up Grant
Activities Funding
Recognition of Achievements
Lifetime Achievement Award
Journal Best Paper Award
Activities Endorsement
Professional Advancement
Rising Star Awards
Clinical Visiting Fellowships
Open Positions
Talent Pool
Library
To landing page
Congress Resources
UEG Week on-demand
Abstracts
Posters
Guideline Resources
Education Resources
Image Hub
Webinars
Mistakes in... articles
Contact us
Young GI
Patients
Industry
Press
Author
Marla C. Dubinsky
SYMPTOMATIC IMPROVEMENT OBSERVED WITHIN 2 DAYS OF ETRASIMOD INDUCTION THERAPY: RESULTS FROM ELEVATE UC 52 AND ELEVATE UC 12 STUDIES IN PATIENTS WITH ULCERATIVE COLITIS
Marla C. Dubinsky
et al.
BIOMARKERS AND BOWEL URGENCY IN RESPONSE TO MIRIKIZUMAB FOR ULCERATIVE COLITIS
BIOMARKERS AND BOWEL URGENCY IN RESPONSE TO MIRIKIZUMAB FOR ULCERATIVE COLITIS
Marla C. Dubinsky
et al.
CLINICAL AND HEALTH OUTCOMES ASSOCIATED WITH TREATMENT SEQUENCES FOR MODERATE-TO-SEVERE ULCERATIVE COLITIS
Can we prevent IBD by targeting the intestinal microbiota?
Marla C. Dubinsky
COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Marla C. Dubinsky
et al.
Targeting inflammation to improve long-term outcomes in UC (Bristol Myers Squibb)
Marla C. Dubinsky
et al.
SYMPTOMS AND LABORATORY VALUES AS PROXIES FOR ENDOSCOPIC AND HISTOLOGIC CLINICAL ENDPOINTS IN ULCERATIVE COLITIS: A MEDIATION ANALYSIS BASED ON UPADACITINIB PHASE 3 INDUCTION TRIALS
Marla C. Dubinsky
et al.
ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB
Marla C. Dubinsky
et al.
Effectively moving forward: Shining without diminishing
Marla C. Dubinsky
Weighing up treatment options in UC: how do we interpret the evidence for JAK inhibition? (Pfizer)
Marla C. Dubinsky
et al.
PREGNANCY OUTCOMES IN THE OZANIMOD CLINICAL DEVELOPMENT PROGRAM IN ULCERATIVE COLITIS, CROHN’S DISEASE, AND RELAPSING MULTIPLE SCLEROSIS
Marla C. Dubinsky
et al.
COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Marla C. Dubinsky
COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FRO
Marla C. Dubinsky
et al.
Most Patients with Ulcerative Colitis ‘Can’t Wait’: The Impact and Clinical Assessment of Bowel Urgency (PeerVoice)
Marla C. Dubinsky
et al.
JAK of all trades, master of IBD? Refocusing our clinical expectations (AbbVie)
Marla C. Dubinsky
et al.
CLINICAL AND HEALTH OUTCOMES ASSOCIATED WITH TREATMENT SEQUENCES FOR MODERATE-TO-SEVERE ULCERATIVE COLITIS
Marla C. Dubinsky
et al.
ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS
Marla C. Dubinsky
et al.
It takes two to tango in UC: let’s get in sync with our patients (Pfizer Inc.) (Complete Session)
Marla C. Dubinsky
et al.
Item 1 - 20 / 52
1
2
3
Chat with us
, powered by
LiveChat